Preservation of RNA for functional genomic studies: A multidisciplinary tumor bank protocol

Scott R. Florell, Cheryl M. Coffin, Joseph A. Holden, James W. Zimmermann, John W. Gerwels, Bradley K. Summers, David A. Jones, Sancy Leachman

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

Few human tumors are collected such that RNA is preserved for molecular analysis. Completion of the Human Genome Project will soon result in the identification of more than 100,000 new genes. Consequently, increasing attention is being diverted to identifying the function of these newly described genes. Here we describe a multidisciplinary tumor bank procurement protocol that preserves both the integrity of tissue for pathologic diagnosis, and the RNA for molecular analyses. Freshly excised normal skin was obtained from five patients undergoing wound reconstruction following Mohs micrographic surgery for cutaneous neoplasia. Tissues treated for 24 hours with RNAlater were compared histologically and immunohistochemically to tissues not treated with RNAlater. Immunohistochemical stains studied included: CD45, CEA, cytokeratin AE1/3, vimentin, S-100, and CD34 on formalin-fixed, paraffin embedded tissue and CD45 staining of frozen tissue. Slides were blinded and evaluated independently by three pathologists. The histologic and immunohistochemical parameters of tissue stored in RNAlater were indistinguishable from tissue processed in standard fashion with the exception of S-100 stain which failed to identify melanocytes or Langerhan's cells within the epidermis in any of the RNAlater-treated tissues. Interestingly, nerve trunks within the dermis stained appropriately for S-100. Multiple non-cutaneous autopsy tissues were treated with RNAlater, formalin, liquid nitrogen (LN2), and TRIzol Reagent®. The pathologists were unable to distinguish between tissues treated with RNAlater, formalin, or frozen in LN2, but could easily distinguish tissues treated with TRIzol Reagent because of extensive cytolysis. RNA was isolated from a portion of the tissue treated with RNAlater and used for molecular studies including Northern blotting and microarray analysis. RNA was adequate for Northern blot analysis and mRNA purified from RNAlater -treated tissues consistently provided excellent templates for reverse transcription and subsequent microarray analysis. We conclude that tissues treated with RNAlater before routine processing are indistinguishable histologically and immunohistochemically from tissues processed in routine fashion and that the RNA isolated from these tissues is of high quality and can be used for molecular studies. Based on this study, we developed a multidisciplinary tumor bank procurement protocol in which fresh tissue from resection specimens are routinely stored in RNAlater at the time of preliminary dissection. Thus, precious human tissue can be utilized for functional genomic studies without compromising the tissue's diagnostic and prognostic qualities.

Original languageEnglish (US)
Pages (from-to)116-128
Number of pages13
JournalModern Pathology
Volume14
Issue number2
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

RNA
Neoplasms
Formaldehyde
Microarray Analysis
Northern Blotting
Keratin-3
Coloring Agents
Mohs Surgery
Human Genome Project
Skin
Langerhans Cells
Melanocytes
Vimentin
Dermis
Epidermis
Paraffin
Genes
Reverse Transcription
Dissection
Autopsy

Keywords

  • cDNA microarray
  • Cutaneous malignancy
  • Expression profiling
  • Functional genomics
  • Genome
  • Histology
  • Human genome project
  • Immunohistochemistry
  • RNA
  • RNAlater
  • Skin cancer
  • Surgical pathology

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Florell, S. R., Coffin, C. M., Holden, J. A., Zimmermann, J. W., Gerwels, J. W., Summers, B. K., ... Leachman, S. (2001). Preservation of RNA for functional genomic studies: A multidisciplinary tumor bank protocol. Modern Pathology, 14(2), 116-128. https://doi.org/10.1038/modpathol.3880267

Preservation of RNA for functional genomic studies : A multidisciplinary tumor bank protocol. / Florell, Scott R.; Coffin, Cheryl M.; Holden, Joseph A.; Zimmermann, James W.; Gerwels, John W.; Summers, Bradley K.; Jones, David A.; Leachman, Sancy.

In: Modern Pathology, Vol. 14, No. 2, 2001, p. 116-128.

Research output: Contribution to journalArticle

Florell, SR, Coffin, CM, Holden, JA, Zimmermann, JW, Gerwels, JW, Summers, BK, Jones, DA & Leachman, S 2001, 'Preservation of RNA for functional genomic studies: A multidisciplinary tumor bank protocol', Modern Pathology, vol. 14, no. 2, pp. 116-128. https://doi.org/10.1038/modpathol.3880267
Florell SR, Coffin CM, Holden JA, Zimmermann JW, Gerwels JW, Summers BK et al. Preservation of RNA for functional genomic studies: A multidisciplinary tumor bank protocol. Modern Pathology. 2001;14(2):116-128. https://doi.org/10.1038/modpathol.3880267
Florell, Scott R. ; Coffin, Cheryl M. ; Holden, Joseph A. ; Zimmermann, James W. ; Gerwels, John W. ; Summers, Bradley K. ; Jones, David A. ; Leachman, Sancy. / Preservation of RNA for functional genomic studies : A multidisciplinary tumor bank protocol. In: Modern Pathology. 2001 ; Vol. 14, No. 2. pp. 116-128.
@article{5b54fd0a01884f9f85b2a0dda048ca07,
title = "Preservation of RNA for functional genomic studies: A multidisciplinary tumor bank protocol",
abstract = "Few human tumors are collected such that RNA is preserved for molecular analysis. Completion of the Human Genome Project will soon result in the identification of more than 100,000 new genes. Consequently, increasing attention is being diverted to identifying the function of these newly described genes. Here we describe a multidisciplinary tumor bank procurement protocol that preserves both the integrity of tissue for pathologic diagnosis, and the RNA for molecular analyses. Freshly excised normal skin was obtained from five patients undergoing wound reconstruction following Mohs micrographic surgery for cutaneous neoplasia. Tissues treated for 24 hours with RNAlater™ were compared histologically and immunohistochemically to tissues not treated with RNAlater. Immunohistochemical stains studied included: CD45, CEA, cytokeratin AE1/3, vimentin, S-100, and CD34 on formalin-fixed, paraffin embedded tissue and CD45 staining of frozen tissue. Slides were blinded and evaluated independently by three pathologists. The histologic and immunohistochemical parameters of tissue stored in RNAlater were indistinguishable from tissue processed in standard fashion with the exception of S-100 stain which failed to identify melanocytes or Langerhan's cells within the epidermis in any of the RNAlater-treated tissues. Interestingly, nerve trunks within the dermis stained appropriately for S-100. Multiple non-cutaneous autopsy tissues were treated with RNAlater, formalin, liquid nitrogen (LN2), and TRIzol Reagent{\circledR}. The pathologists were unable to distinguish between tissues treated with RNAlater, formalin, or frozen in LN2, but could easily distinguish tissues treated with TRIzol Reagent because of extensive cytolysis. RNA was isolated from a portion of the tissue treated with RNAlater and used for molecular studies including Northern blotting and microarray analysis. RNA was adequate for Northern blot analysis and mRNA purified from RNAlater -treated tissues consistently provided excellent templates for reverse transcription and subsequent microarray analysis. We conclude that tissues treated with RNAlater before routine processing are indistinguishable histologically and immunohistochemically from tissues processed in routine fashion and that the RNA isolated from these tissues is of high quality and can be used for molecular studies. Based on this study, we developed a multidisciplinary tumor bank procurement protocol in which fresh tissue from resection specimens are routinely stored in RNAlater at the time of preliminary dissection. Thus, precious human tissue can be utilized for functional genomic studies without compromising the tissue's diagnostic and prognostic qualities.",
keywords = "cDNA microarray, Cutaneous malignancy, Expression profiling, Functional genomics, Genome, Histology, Human genome project, Immunohistochemistry, RNA, RNAlater, Skin cancer, Surgical pathology",
author = "Florell, {Scott R.} and Coffin, {Cheryl M.} and Holden, {Joseph A.} and Zimmermann, {James W.} and Gerwels, {John W.} and Summers, {Bradley K.} and Jones, {David A.} and Sancy Leachman",
year = "2001",
doi = "10.1038/modpathol.3880267",
language = "English (US)",
volume = "14",
pages = "116--128",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Preservation of RNA for functional genomic studies

T2 - A multidisciplinary tumor bank protocol

AU - Florell, Scott R.

AU - Coffin, Cheryl M.

AU - Holden, Joseph A.

AU - Zimmermann, James W.

AU - Gerwels, John W.

AU - Summers, Bradley K.

AU - Jones, David A.

AU - Leachman, Sancy

PY - 2001

Y1 - 2001

N2 - Few human tumors are collected such that RNA is preserved for molecular analysis. Completion of the Human Genome Project will soon result in the identification of more than 100,000 new genes. Consequently, increasing attention is being diverted to identifying the function of these newly described genes. Here we describe a multidisciplinary tumor bank procurement protocol that preserves both the integrity of tissue for pathologic diagnosis, and the RNA for molecular analyses. Freshly excised normal skin was obtained from five patients undergoing wound reconstruction following Mohs micrographic surgery for cutaneous neoplasia. Tissues treated for 24 hours with RNAlater™ were compared histologically and immunohistochemically to tissues not treated with RNAlater. Immunohistochemical stains studied included: CD45, CEA, cytokeratin AE1/3, vimentin, S-100, and CD34 on formalin-fixed, paraffin embedded tissue and CD45 staining of frozen tissue. Slides were blinded and evaluated independently by three pathologists. The histologic and immunohistochemical parameters of tissue stored in RNAlater were indistinguishable from tissue processed in standard fashion with the exception of S-100 stain which failed to identify melanocytes or Langerhan's cells within the epidermis in any of the RNAlater-treated tissues. Interestingly, nerve trunks within the dermis stained appropriately for S-100. Multiple non-cutaneous autopsy tissues were treated with RNAlater, formalin, liquid nitrogen (LN2), and TRIzol Reagent®. The pathologists were unable to distinguish between tissues treated with RNAlater, formalin, or frozen in LN2, but could easily distinguish tissues treated with TRIzol Reagent because of extensive cytolysis. RNA was isolated from a portion of the tissue treated with RNAlater and used for molecular studies including Northern blotting and microarray analysis. RNA was adequate for Northern blot analysis and mRNA purified from RNAlater -treated tissues consistently provided excellent templates for reverse transcription and subsequent microarray analysis. We conclude that tissues treated with RNAlater before routine processing are indistinguishable histologically and immunohistochemically from tissues processed in routine fashion and that the RNA isolated from these tissues is of high quality and can be used for molecular studies. Based on this study, we developed a multidisciplinary tumor bank procurement protocol in which fresh tissue from resection specimens are routinely stored in RNAlater at the time of preliminary dissection. Thus, precious human tissue can be utilized for functional genomic studies without compromising the tissue's diagnostic and prognostic qualities.

AB - Few human tumors are collected such that RNA is preserved for molecular analysis. Completion of the Human Genome Project will soon result in the identification of more than 100,000 new genes. Consequently, increasing attention is being diverted to identifying the function of these newly described genes. Here we describe a multidisciplinary tumor bank procurement protocol that preserves both the integrity of tissue for pathologic diagnosis, and the RNA for molecular analyses. Freshly excised normal skin was obtained from five patients undergoing wound reconstruction following Mohs micrographic surgery for cutaneous neoplasia. Tissues treated for 24 hours with RNAlater™ were compared histologically and immunohistochemically to tissues not treated with RNAlater. Immunohistochemical stains studied included: CD45, CEA, cytokeratin AE1/3, vimentin, S-100, and CD34 on formalin-fixed, paraffin embedded tissue and CD45 staining of frozen tissue. Slides were blinded and evaluated independently by three pathologists. The histologic and immunohistochemical parameters of tissue stored in RNAlater were indistinguishable from tissue processed in standard fashion with the exception of S-100 stain which failed to identify melanocytes or Langerhan's cells within the epidermis in any of the RNAlater-treated tissues. Interestingly, nerve trunks within the dermis stained appropriately for S-100. Multiple non-cutaneous autopsy tissues were treated with RNAlater, formalin, liquid nitrogen (LN2), and TRIzol Reagent®. The pathologists were unable to distinguish between tissues treated with RNAlater, formalin, or frozen in LN2, but could easily distinguish tissues treated with TRIzol Reagent because of extensive cytolysis. RNA was isolated from a portion of the tissue treated with RNAlater and used for molecular studies including Northern blotting and microarray analysis. RNA was adequate for Northern blot analysis and mRNA purified from RNAlater -treated tissues consistently provided excellent templates for reverse transcription and subsequent microarray analysis. We conclude that tissues treated with RNAlater before routine processing are indistinguishable histologically and immunohistochemically from tissues processed in routine fashion and that the RNA isolated from these tissues is of high quality and can be used for molecular studies. Based on this study, we developed a multidisciplinary tumor bank procurement protocol in which fresh tissue from resection specimens are routinely stored in RNAlater at the time of preliminary dissection. Thus, precious human tissue can be utilized for functional genomic studies without compromising the tissue's diagnostic and prognostic qualities.

KW - cDNA microarray

KW - Cutaneous malignancy

KW - Expression profiling

KW - Functional genomics

KW - Genome

KW - Histology

KW - Human genome project

KW - Immunohistochemistry

KW - RNA

KW - RNAlater

KW - Skin cancer

KW - Surgical pathology

UR - http://www.scopus.com/inward/record.url?scp=0035108505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035108505&partnerID=8YFLogxK

U2 - 10.1038/modpathol.3880267

DO - 10.1038/modpathol.3880267

M3 - Article

C2 - 11235903

AN - SCOPUS:0035108505

VL - 14

SP - 116

EP - 128

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 2

ER -